医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sosei Appoints Peter Bains as CEO

2016年06月24日 PM07:14
このエントリーをはてなブックマークに追加


 

TOKYO

Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces the appointment of Mr Peter Bains as Representative Executive Officer and Chief Executive Officer (CEO) effective from June 24 2016 upon approval by the Board of Directors following Sosei Group’s Annual General Meeting. At the same time, Mr Shinichi Tamura, Sosei founder and Group Chairman, President and CEO, is appointed as Representative Executive Officer and Executive Chairman. Peter Bains will continue to report to Mr Shinichi Tamura.

1.

  The reason for appointment

To further strengthen/develop the system of management to improve our corporate
value and reinforce the management base

 
2. The name and title of Representative Executive Officer
Name: Peter Bains
Title: Representative Executive Officer and Chief Executive Officer (CEO)
 

3.

 

Brief summary of Peter Bains

Date of birth   Profile  

Ownership of
shares of Sosei

July 26 1957 March 1996: General Manager of SmithKline Beecham plc. (GlaxoSmithKline) 0
January 2001: Senior Vice President, GlaxoSmithKline International Commercial Development
June 2009: Director of Peter Bains Consulting Limited.
January 2010: Non-executive Board Director at Syngene International Limited
June 2010: Non-executive Director at Sosei Group Corporation
February 2015: Director at Heptares Therapeutics Ltd.
February 2015: Executive Director and CEO at Syngene International Limited
  April 2016:Representative Executive Officer and Chief Operating Officer at Sosei Group Corporation  
 
4.   Effective date
As of June 24 2016
 

About Sosei
Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei have established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei have already delivered two bronchodilators for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide.

For further information about Sosei, please visit www.sosei.com/en.

Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160624005208/en/

CONTACT

Enquiries:
Sosei Group Corporation
Tokyo Office
Harumi
BANSE, +81-(0)3-5210-3399
Investor Relations
hbanse@sosei.com
or
London
Office
Kathryn LYDON, +44-(0)20-7691-0983
Corporate
Communications
klydon@sosei.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 国际纳米技术展览暨研讨会——2017纳米科技展将为您带来尖端技术与材料的最新资讯,令超智能社会触手可及
  • Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies
  • Bioventus选择MEDSERVICE作为DUROLANE®在俄罗斯的经销商
  • “nano tech 2017 国際ナノテクノロジー総合展・技術会議”開催、超スマート社会の実現に貢献する最先端技術・材料の最新情報を発信!
  • nano tech 2017, the International Nanotechnology Exhibition & Conference, Brings You the Latest Information on the Cutting Edge Technologies and Materials Making the Super Smart Society a Reality